黄芪甲苷脂质聚合物纳米粒对缺血再灌注损伤诱导大鼠模型的影响

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1050 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of astragaloside Ⅳ-lipid polymerhybrid nanoparticles (AA-LPNs) on rat model induced by ischemia-reperfusion injury. Methods AA-LPNs was prepared by nano-precipitation method. Sixteen clean SD rats were selected and divided into the conventional group (8 rats) and the study group (8 rats) according to the random number table method. The conventional group was given astragaloside Ⅳ (AA) (40 mg/kg, 1.5 ml), and the study group was given AA-LPNs (40 mg/kg, 1.5 ml). The pharmacokinetic parameters of the two groups were compared (drug half-life [t1/2], peak time [Tmax], peak concentration [Cmax], area under concentration-time curve [AUC] [AUClast, AUCall], mean retention time [MRT] [MRTlast, MRTall]). Another 60 rats were selected, 15 of which were randomly selected as the sham operation group, and the rest were constructed as ischemia-reperfusion injury induced rat models. After successful modeling, the rats were divided into model group, AA group, and AA-LPNs group according to random number table method, with 15 rats in each group. Twenty four hours after modeling, the AA group and AA-LPNs group were given 40 mg/kg intragastric administration, while the sham operation group and model group were given 0.9% sodium chloride solution, once a day, for consecutive four weeks. After the experiment, the serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA) in four groups were detected. TUNEL assay was used to detect the apoptosis of myocardial cells in the four groups. Results The AA-LPNs prepared in this study were spherical and uniformly round, with an average dynamic diameter of (180±23) nm. t1/2, Tmax, AUClast, AUCall, and MRTall in the study group were higher than those in the conventional group, and the differences were statistically significant (P ＜ 0.05). Serum CK, LDH, MDA level and apoptosis rate in model group were higher than those in sham operation group, while SOD level was lower than that in sham operation group, the differences were highly statistically significant (P ＜ 0.01). Serum CK, LDH, MDA level and apoptosis rate in AA group and AA-LPNs group were lower than those in model group, while SOD level was higher than that in model group, the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Serum CK, LDH, MDA level and apoptosis rate in AA-LPNs group were lower than those in AA group, while SOD level was higher than that in AA group, the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Conclusion AA-LPNs has a protective effect on myocardial cells in rats with ischemia-reperfusion injury.

Key words： Astragaloside Ⅳ Bioavailability Ischemia-reperfusion injury Apoptosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAI Zhikun FENG Qimao WANG Su HU Xiaozhen

Cite this article:

LAI Zhikun FENG Qimao WANG Su HU Xiaozhen. Effects of astragaloside Ⅳ-lipid polymerhybrid nanoparticles on rat model induced by ischemia-reperfusion injury#br#[J]. 中国医药导报, 2022, 19(11): 25-29.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I11/25

[1] Stephenson J，Nutma E，Valk P，et al. Inflammation in CNS neurodegenerative diseases [J]. Immunology，2018， 154（2）：204-219.
[2] Luo Y，Wan Q，Xu M，et al. Nutritional preconditioning induced by astragaloside Ⅳ on isolated hearts and cardiomyocytes against myocardial ischemia injury via improving Bcl-2-mediated mitochondrial function [J]. Chem Biol Interact，2019，309：108723.
[3] 王莉新，吴文斌，胥孜杭，等.黄芪甲苷通过诱导M1型巨噬细胞极化发挥抗肿瘤作用的机制[J].中国实验方剂学杂志，2019，25（14）：19-24.
[4] Li Y，Ye Y，Chen H. Astragaloside Ⅳ inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB [J]. Biomed Pharmacother，2018，99：134-141.
[5] 杨晓燕，曹艳玲.黄芪甲苷溶解性能及大鼠体内代谢研究[C]//中华中医药学会中药分析分会第六届学术交流会论文集，2013：326-333.
[6] 马紫薇，徐颖，李孝文，等.羟基喜树碱脂质聚合物杂化纳米粒的制备及体内外性能评价[J].沈阳药科大学学报，2020，37（9）：769-777.
[7] 闫飞，施江培，陈海珍，等.载五味子乙素F127修饰脂质聚合物纳米粒抑制乳腺癌肺转移的研究[J].中国中药杂志，2020，45（21）：5177-5183.
[8] 孙涛，李雅，郭志华，等.血速升颗粒对心肌缺血再灌注大鼠心肌组织的保护作用及机制研究[J].临床和实验医学杂志，2020，19（24）：2581-2585.
[9] 胡海燕.草酸钙结晶肾损伤模型小鼠肾小管上皮细胞EMT发生与法舒地尔保护作用及机制的研究[D].上海：第二军医大学，2013.
[10] 郁梅.黄芪甲苷纳米乳的处方筛选研究[J].内蒙古中医药，2016，35（7）：79-80.
[11] 陈佳，龚涛.黄芪甲苷纳米结构脂质载体冻干粉的制备及其初步质量评价[J].华西药学杂志，2011，26（6）：530-533.
[12] 张小飞，果秋婷，邹俊波，等.黄芪甲苷自乳化释药系统的制备及大鼠在体肠吸收研究[J].中草药，2019，50（13）：3037-3043.
[13] Liu Y，Zhao YQ，Liu JG，et al. Wheat germ agglutinin modification of lipid–polymer hybrid nanoparticles：enhanced cellular uptake and bioadhesion [J]. RSC Adv，2016，42：36125-36135.
[14] Rao S，Prestidge CA. Polymer-lipid hybrid systems：merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery [J]. Expert Opin Drug Deliv，2016，13（5）：691-707.
[15] 林霞，李娜，李金蔚，等.口服胰岛素肠溶聚合物脂质杂化纳米粒的制备与评价[J].中国药科大学学报，2019， 50（3）：308-316.
[16] 曾诚，许芳，杨晓艺，等.双配体修饰脂质聚合物杂化纳米粒的制备及细胞摄取研究[J].西北药学杂志，2020， 35（2）：243-248.
[17] 沈俊楠，姚文栋.载白藜芦醇PLGA纳米粒的制备及其体内外评价[J].中国现代应用药学，2021，38（2）：167-172.
[18] 姚雪敏，荆鸣，蔡馥伊，等.穿膜肽GGPFV修饰的柔红霉素/薯蓣皂苷脂质体的处方优化及细胞毒性研究[J].中国药房，2020，31（21）：2579-2584.
[19] 郑爽，俞建东，陈礼迎，等.共载新型二甲双胍聚合物和多柔比星的核膜型脂质纳米粒制备及治疗乳腺癌的研究[J].药学学报，2019，54（12）：2316-2325.
[20] 刘宏盼，奚泉，周建平，等.RGD肽修饰紫杉醇聚合物纳米粒的制备及其药效学研究[J].中国药科大学学报，2013，44（3）：228-233.
[21] 雷萌，王雪源，苗航，等.叶酸靶向聚合物纳米粒共传输紫杉醇和吉西他滨用于乳腺癌的治疗[J].中国药学（英文版），2020，29（10）：701-710.
[22] 杨竞霄，李菁华，李炜，等.葛根素减轻线粒体氧化应激改善大鼠心脏缺血再灌注损伤[J].山西医科大学学报，2021，52（1）：38-43.
[23] 刘超，王明娟，范彦芳，等.丹皮酚通过上调SIRT1减轻大鼠心肌缺血再灌注损伤[J].河北医学，2020，26（6）：917-921.
[24] 张博雅，高晟.黄芪甲苷对心肌细胞保护作用机制的研究进展[J].天津医药，2020，48（2）：156-160.
[25] 黄初生，邓海龙，毕笑寒，等.体外循环心脏瓣膜置换术患者围手术期氧磷酶1与超氧化物歧化酶和丙二醛的变化及相关性[J].中国心血管病研究，2021，19（11）：982-985.
[26] 薛丽娟，张文龙，李灵芝.白藜芦醇苷对心脏缺血再灌注损伤大鼠的保护作用[J].中成药，2019，41（2）：451-453.